Literature DB >> 25073885

Continuous rhythm monitoring for ventricular arrhythmias after alcohol septal ablation for hypertrophic cardiomyopathy.

Jippe C Balt1, Maurits C E F Wijffels1, Lucas V A Boersma1, Eric F D Wever1, Jurriën M ten Berg1.   

Abstract

OBJECTIVE: The purpose of the present study was to determine the incidence of ventricular arrhythmias before and after alcohol septal ablation (ASA).
BACKGROUND: In patients with hypertrophic obstructive cardiomyopathy (HOCM), gradient reduction by ASA is an alternative for surgical myectomy. However, concerns exist about whether the induction of a myocardial scar during ASA may create substrate for ventricular arrhythmias.
METHODS: The study group consisted of 44 patients in whom ASA was performed for symptomatic, drug-refractory hypertrophic cardiomyopathy. Continuous rhythm monitoring was obtained by implantable loop recorder (n=30) or pacemaker (n=14). Occurrence of ventricular and supraventricular arrhythmias before and after ASA was noted, retrospectively.
RESULTS: The ASA procedure was considered successful (resting gradient <30 mm Hg, and provoked gradient <50 mm Hg at 4 months in combination with NYHA Class functional status ≤2) in 30 (68%) patients. Rhythm monitoring before ASA was available in 28 patients. The median duration of rhythm monitoring after ASA was 3.0 years (IQR 1.3-4.3). Sustained VT/VF within 30 days after ASA occurred in three patients (7%), including 2 cases of procedural VF, while no VT/VF was observed before ASA (p=0.10). No sustained VT/VF was observed >30 days after ASA. No cardiac deaths occurred during follow-up.
CONCLUSIONS: In a low-risk cohort of patients who underwent ASA, in which continuous rhythm monitoring was performed, sustained VT or VF within 30 days occurred in 3 patients (7%) while no VT/VF was observed before ASA. During long-term follow-up, no sustained VT or VF was observed >30 days after ASA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25073885     DOI: 10.1136/heartjnl-2014-305593

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  5 in total

1.  Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy.

Authors:  Angelos G Rigopoulos; Silke Daci; Barbara Pfeiffer; Konstadia Papadopoulou; Anna Neugebauer; Hubert Seggewiss
Journal:  Clin Res Cardiol       Date:  2016-06-06       Impact factor: 5.460

Review 2.  [Indications for implantable loop recorders in patients with channelopathies and ventricular tachycardias].

Authors:  Julia Köbe; Kristina Wasmer; Florian Reinke; Lars Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2016-12

3.  Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy.

Authors:  Mengyao Zhou; Shengjun Ta; Rebecca T Hahn; David H Hsi; Martin B Leon; Rui Hu; Jun Zhang; Lei Zuo; Jing Li; Jing Wang; Bo Wang; Xiaoli Zhu; Jiani Liu; Yupeng Han; Xiaojuan Li; Bo Xu; Lei Zhang; Lihong Hou; Chao Han; Jincheng Liu; Liwen Liu
Journal:  JAMA Cardiol       Date:  2022-05-01       Impact factor: 30.154

Review 4.  Arrhythmia Monitoring for Risk Stratification in Hypertrophic Cardiomyopathy.

Authors:  Darson Du; Christopher O Y Li; Kevin Ong; Ashkan Parsa; Adaya Weissler-Snir; Jeffrey B Geske; Zachary Laksman
Journal:  CJC Open       Date:  2022-01-07

5.  Septal myectomy with mitral valve surgery in patients after alcohol septal ablation.

Authors:  Kostiantyn V Rudenko; Vasyl V Lazoryshynets; Lidiia O Nevmerzhytska; Mariia O Tregubova; Polina A Danchenko
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-05-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.